This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

Exclusion Criteria

• •Patients with known brain metastases.
• •Previous high dose chemotherapy requiring stem cell rescue.
• •Prior irradiation to \>25% of the bone marrow.
• •Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
• •Current active treatment in another clinical study.
• •Pregnancy or breast feeding.
• •Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.